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SOCIETY NEWS
ASHG Statement* on Direct-to-Consumer Genetic Testing
in the United States
* Approved by the ASHG Board of Directors in January 2007.
Direct-to-consumer (DTC) genetic testing has been gaining prom-
inence over the past several years.1 Proponents of DTC testing
cite beneﬁts that include increased consumer access to testing,
greater consumer autonomy and empowerment, and enhanced
privacy of the information obtained. Critics of DTC genetic test-
ing have pointed to the risks that consumers will choose testing
without adequate context or counseling, will receive tests from
laboratories of dubious quality, and will be misled by unproven
claims of beneﬁt.
Currently, DTC genetic testing is permitted in about half the
states2 and is subject to little oversight at the federal level. In July
2006, the Government Accountability Ofﬁce issued a report doc-
umenting troubling marketing practices by some DTC testing
companies,3 and the Federal Trade Commission (FTC) issued a
consumer alert cautioning consumers to be skeptical about claims
made by some DTC companies.4 Internationally, several countries
have issued reports cautioning against its use,5–7 and several Eu-
ropean countries have banned or are considering banning it
entirely.
DTC testing has emerged during a period of rapid growth in
the number of genetic tests. Today, there are more than 1,100
genetic tests available clinically, and several hundred more are
available in research settings. Although most genetic testing is
currently available only through a health care provider, an in-
creasing variety of tests are being offered DTC, often without any
health care provider involvement or counseling. The range of
tests available DTC is broad, from tests for single-gene disorders,
such as cystic ﬁbrosis, to tests for predisposition to complex,mul-
tifactorial diseases, such as depression and cardiovascular disease.
In addition to providing test results DTC, some companies also
make recommendations regarding lifestyle changes on the basis
of these results, such as changes in diet or use of nutritional
supplements.
Ensuring adequate information, high-quality laboratories, and
accurate claims and interpretation of test results is important for
all genetic tests, including those provided DTC. At the same time,
a one-size-ﬁts-all approach is not appropriate for DTC tests, be-
cause the types of tests being offered are heterogeneous, and their
consequences are wide ranging. A test may be used to diagnose
disease, to predict risk of future disease, to determine the risk of
passing on a disease to one’s offspring, to aid in therapy selection,
or to guide “lifestyle” choices such as diet and skin care. Different
possible actions may result from different types of tests. For ex-
ample, tests to determine whether someone is a carrier of a mu-
tation for a particular disease may affect the choice of whether
or whom to marry, whether to have children, and whether to
terminate a pregnancy. Thus, the level of evidence required before
a test is offered DTC, and the safeguards appropriate to ensure
adequate consumer protection, will differ depending on what is
being tested for and what the foreseeable consequences of testing
are. Whereas the DTC model may be contraindicated for certain
types of tests, the availability of other tests in the absence of a
health care provider may not compromise, and may even foster,
patient health. This policy statement does not attempt to set the
dividing line between those tests that should be offered DTC and
those that should not; rather, it sets forth principles that should
govern all health-related genetic tests that are offered DTC.
Scope of this Statement
While DTC testing also encompasses paternity and ancestry test-
ing, this policy statement addresses solely those genetic tests that
make health-related claims or that directly affect health care de-
cision making. In addition, although “DTC” is sometimes used
to refer to tests advertised but not sold DTC, this policy statement
focuses on tests that can be ordered directly by a consumer and
whose results are reported DTC without an independent health
care provider—one not employed by the testing company—serv-
ing as an intermediary.
Context
DTC genetic testing differs from traditional genetic testing in that
consumers order tests and receive test results without an inde-
pendent provider serving as an intermediary.Whether a company
is permitted to provide DTC genetic-testing services is a matter
of state law. Currently, about half the states permit DTC genetic
testing.2 Additionally, although some states require a provider to
order a test on behalf of a patient, this requirement can generally
be fulﬁlled by a physician employed by the laboratory. SomeDTC
companies offer genetic counseling, while others do not.
DTC tests are typically advertised and sold over the Internet.
After the consumer orders the test, the testing company sends a
sample-collection kit (e.g., buccal swab or blood-spot collection).
The consumer sends back the sample, and the company performs
the test and sends a test report via the Internet or the mail. This
context has led to the concern that consumers will not receive
adequate counseling—either in advance, to ensure that the test
is appropriate, or on receipt of test results, to ensure that con-
sumers comprehend the complex information and understand
the consequences of testing for themselves and their family
members.
Quality
Because of the fragmented regulatory environment for genetic
testing in general, there is concern that the quality of the tests
offered DTC may be inadequate. For a test to be of good quality,
the laboratory performing it must be able to obtain the correct
answer reliably, meaning that it detects a particular genetic var-
iant when it is present and does not detect the variant when it
is absent. A test’s accuracy is referred to as “analytic validity.”
Further, there must be adequate scientiﬁc evidence to support the
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correlation between the genetic variant and a particular health
condition or risk—the so-called clinical validity.
Currently, the federal government exercises limited oversight
of the analytic validity of genetic tests and virtually no oversight
of their clinical validity. Laboratories that perform clinical genetic
testing must be certiﬁed under the Clinical Laboratory Improve-
ment Amendments of 1988 (CLIA). However, although CLIA im-
poses basic requirements that address personnel qualiﬁcations,
quality-control standards, and documentation and validation of
tests and procedures, it does not address clinical validity or claims
made by the laboratory regarding the tests. Nor does CLIA yet
contain a “specialty area” for most genetic tests, which hampers
the government’s ability to determine whether tests are being
performed correctly.8 Although the Centers for Medicare and
Medicaid Services (CMS) stated for several years that it intended
to create a genetic-testing specialty, the agency suddenly reversed
course in 2006, stating that no specialty would be issued.
The level of scrutiny by the U.S. Food and Drug Administration
(FDA) differs markedly depending on whether the test is per-
formed using a commercial “test kit” or a laboratory-developed
test method. Whereas the FDA reviews the analytic and clinical
validity and the labeling of commercial test kits before they are
marketed and requires postmarket adverse-event reporting if
there are problems with the kit, there is no premarket review of
laboratory-developed tests, nor is there any requirement to report
adverse events. Recently, the FDA indicated that it plans to reg-
ulate a small subset of laboratory-developed tests known as “in
vitro diagnostic multivariate index assays,”9 but this is a very
narrow category of tests that will exclude the vast majority of
genetic tests offered by clinical laboratories.
The lack of a coherent regulatory landscape to ensure quality
is not unique to DTC genetic testing, since all other molecular
and biochemical tests are also affected. However, quality concerns
are particularly acute in the DTC context because of the low bar-
rier to market entry, the complexity of the information that con-
sumers need to understand to make an informed decision, and
the lack of provider scrutiny. Consumers are at a signiﬁcant risk
of selecting tests with unproven beneﬁt, of obtaining testing ser-
vices from laboratories of dubious quality, and of making deci-
sions without timely and accurate genetic counseling.
Claims
Claims made regarding DTC genetic tests may in some cases be
exaggerated or unsupported by scientiﬁc evidence. Exaggerated
or unsupported claims may lead consumers to get tested inap-
propriately or to have false expectations regarding the beneﬁts
of testing. Further, consumers may make unwarranted, and even
irrevocable, decisions on the basis of test results and associated
information, such as the decision to terminate a pregnancy, to
forgo needed treatment, or to pursue unproven therapies.
Some DTC companies use privacy as a marketing tool, touting
the beneﬁts of obtaining genetic testing outside the health care
system and thereby avoiding the risks of having genetic infor-
mation contained in a medical record. However, these companies
do not necessarily disclose their privacy policies or explain that
a patient’s subsequent disclosure of the test results to a physician
may lead to the information becoming part of his or her medical
record. Further, DTC companies are not necessarily subject to the
health privacy regulations issued pursuant to theHeath Insurance
Portability and Accountability Act (HIPAA), leaving consumers
vulnerable to having their information used or disclosed in a
manner that would be impermissible in the health care system.
Federal law prohibits companies from using unfair, deceptive,
or fraudulent trade practices, including making false or mislead-
ing advertising claims. This law, in theory, prohibits clearly false
genetic-testing claims. Several complaints have been ﬁled and
are pending with the FTC about a speciﬁc DTC genetic-testing
company, and the FTC recently issued a consumer alert warning
the public that “some of these [DTC] tests lack scientiﬁc validity,
and others provide medical results that are meaningful only in
the context of a full medical evaluation.”4 The FTC has not, how-
ever, taken direct action against any DTC genetic-testing com-
pany. Furthermore, with respect to tests for which some scien-
tiﬁc support exists but for which claims are exaggerated or pro-
vide incomplete information, FTC regulators may be insufﬁ-
ciently knowledgeable to detect the misleading nature of such
claims. It also must be recognized that there are limits to the
government’s ability to restrict commercial speech. Finally, al-
though the FDA has the authority to regulate claims for products
it regulates, the agency currently does not regulate most genetic
tests and therefore does not regulate their claims.
On the basis of the foregoing analysis, the American Society of
Human Genetics makes the following recommendations about
DTC genetic testing.
Recommendations
I. Transparency
To promote transparency and to permit providers and consumers to
make informed decisions about DTC genetic testing, companies must
provide all relevant information about offered tests in a readily acces-
sible and understandable manner.
a. Companies offering DTC genetic testing should disclose the
sensitivity, speciﬁcity, and predictive value of the test, and the
populations for which this information is known, in a readily
understandable and accessible fashion.
b. Companies offering DTC testing should disclose the strength
of scientiﬁc evidence on which any claims of beneﬁt are based,
as well as any limitations to the claimed beneﬁts. For example,
if a disease or condition may be caused by many factors, in-
cluding the presence of a particular genetic variant, the com-
pany should disclose that other factors may cause the con-
dition and that absence of the variant does not mean the
patient is not at risk for the disease.
c. Companies offeringDTC testing should clearly disclose all risks
associated with testing, including psychological risks and risks
to family members.
d. Companies offering DTC testing should disclose the CLIA
certiﬁcation status of the laboratory performing the genetic
testing.
e. Companies offering DTC testing should maintain the privacy
of all genetic information and disclose their privacy policies,
including whether they comply with HIPAA.
f. Companies offering DTC testing and making lifestyle, nutri-
tional, pharmacologic, or other treatment recommendations
on the basis of the results of those tests should disclose the
clinical evidence for and against the efﬁcacy of such inter-
ventions, with respect to those speciﬁc recommendations
and indications.
II. Provider Education
To ensure that providers are aware that genetic tests are being provided
DTC and that some of these tests may lack analytic or clinical validity,
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professional organizations should educate their members regarding the
types of genetic tests offered DTC, so that providers can counsel their
patients about the potential value and limitations of DTC testing.
a. Professional organizations should disseminate information to
their members explaining what DTC testing is, what tests are
offered DTC, and the potential beneﬁts and limitations of such
testing for patients.
III. Test and Laboratory Quality
To ensure the analytic and clinical validity of genetic tests offered DTC
and to ensure that claims made about these tests are truthful and not
misleading, the relevant agencies of the federal government should take
appropriate and targeted regulatory action.
a. CMS should create a genetic-testing specialty under CLIA, to
ensure the analytic validity of tests and the quality of genetic-
testing laboratories.
b. CMS should ensure that all DTC genetic-testing laboratories
are certiﬁed under CLIA and should maintain a publicly ac-
cessible list containing the certiﬁcation status of laboratories.
c. The federal government should take steps to ensure the clinical
validity of DTC tests that make health-related or health care–
affecting claims.
d. The FTC should take action against companies that make false
or misleading claims about DTC tests.
e. The FDA and the FTC should work together to develop guide-
lines for DTC testing companies to follow, to ensure that their
claims are truthful and not misleading and that they ad-
equately convey the scientiﬁc limitations for particular tests.
f. The Centers for Disease Control and Prevention (CDC) should
conduct a study on the impact of DTC testing on consumers,
to assess whether and to what extent consumers are experi-
encing beneﬁt and/or harm from this method of test delivery.
The CDC should also conduct a systematic comparison be-
tween the claims made in DTC advertising and the scientiﬁc
evidence available to support these claims.
Conclusion
DTC genetic testing is a method of marketing genetic tests to
consumers without the involvement of an independent health
care provider. Potential beneﬁts of DTC testing include increased
consumer awareness of and access to testing. In the current en-
vironment, consumers are at risk of harm from DTC testing if
testing is performed by laboratories that are not of high quality,
if tests lack adequate analytic or clinical validity, if claims made
about tests are false or misleading, and if inadequate information
and counseling are provided to permit the consumer to make an
informed decision about whether testing is appropriate and about
what actions to take on the basis of test results.
KATHY HUDSON, GAIL JAVITT, WYLIE BURKE,
and PETER BYERS, with the ASHG SOCIAL ISSUES
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